Methods for the treatment of synucleinopathies

• US 20070293539A1
• Filed: 01/26/2007
• Published: 12/20/2007
• Est. Priority Date: 03/18/2004
• Status: Abandoned Application

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Liu, Zhihua, Lansbury, Peter
• Application Number:
  US11/698,983
• Publication Number:
  US 20070293539A1
• Time in Patent Office: Days
• US Class Current: 514/319
• CPC Class Codes: A61K 31/13 Amines A61K31/04 takes precedence
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs

Abstract

Methods are provided of treating synucleinopathies, such as Parkinson'"'"'s Disease, Diffuse Lewy Body Disease and Multiple System Atrophy, comprising administering to a synucleinopathic subject a farnesyl transferase inhibitor compound.

Claims

1. A method of treating a synucleinopathic subject, the method comprising administering to a synucleinopathic subject a farnesyl transferase inhibitor, or a pharmaceutically acceptable salt form thereof, in a therapeutically effective amount.

2. The method of claim 1, wherein the synucleinopathic subject has a synucleinopathy selected from the group consisting of Parkinson'"'"'s disease, diffuse Lewy body disease, and multiple system atrophy disorder.

3. The method of claim 1, wherein the synucleinopathic subject has Parkinson'"'"'s disease.

4. The method of claim 1, 2, or 3, wherein the subject is a human.

5. The method of claim 4, wherein the effective amount of the farnesyl transferase inhibitor or a pharmaceutically acceptable salt form thereof comprises about 10 ng/kg of body weight to about 1000 mg/kg of body weight at a frequency of administration from once a day to once a month.

6. The method of claim 1, 2, or 3 further comprising administering to the subject an amount of one or more non-farnesyl transferase inhibitor compounds effective to treat a neurological disorder.

7. The method of claim 6, wherein each non-farnesyl transferase inhibitor compound is selected from the group consisting of dopamine agonist, DOPA decarboxylase inhibitor, dopamine precursor, monoamine oxidase blocker, cathechol O-methyl transferase inhibitor, anticholinergic, and NMDA antagonist.

8. The method of claim 6, wherein each non-farnesyl trasferase inhibitor compound is selected from the group consisting of Memantine, Aricept, and other acetylcholinesterase inhibitors.

9. An article of manufacture comprising packaging material and a farnesyl transferase inhibitor, or a pharmaceutically acceptable salt form thereof, wherein the article of manufacture further comprises a label or package insert indicating that the farnesyl transferase inhibitor can be administered to a subject for treating a synucleinopathy.

10. The article of manufacture of claim 9, wherein the synucleinopathy is selected from the group consisting of:

Parkinson'"'"'s disease, diffuse Lewy body disease, and multiple system atrophy disorder.

11. The article of manufacture of claim 9, wherein the synucleinopathy is Parkinson'"'"'s disease.

12. The article of manufacture of claim 9, 10, or 11, further comprising one or more non-farnesyl transferase inhibitor compounds effective to treat a neurological disorder.

13. The article of manufacture of claim 12, wherein each non-farnesyl transferase inhibitor compound is selected from the group consisting of dopamine agonist, DOPA decarboxylase inhibitor, dopamine precursor, monoamine oxidase blocker, cathechol O-methyl transferase inhibitor, anticholinergic, and NMDA antagonist.

14. The article of manufacture of claim 12, wherein each non-farnesyl trasferase inhibitor compound is selected from the group consisting of Memantine, Aricept, and other acetylcholinesterase inhibitors.